These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 6123587)

  • 21. Presynaptic dopamine receptors in striatal nerve endings: absence of haloperidol-induced supersensitivity.
    Raiteri M; Cerrito F; Casazza G; Levi G
    Adv Biochem Psychopharmacol; 1980; 24():37-43. PubMed ID: 7405669
    [No Abstract]   [Full Text] [Related]  

  • 22. Blood pressure lowering effects of N,N-di-n-propyl-dopamine in rats: evidence for stimulation of peripheral dopamine receptors leading to inhibition of sympathetic vascular tone.
    Cavero I; Lefèvre-Borg F; Gomeni R
    J Pharmacol Exp Ther; 1981 Aug; 218(2):515-24. PubMed ID: 7252851
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chronic haloperidol does not increase specific dopamine receptor binding in rat frontal cortex.
    Meller E; Bohmaker K; Rosengarten H; Friedhoff AJ
    Res Commun Chem Pathol Pharmacol; 1982 Sep; 37(3):323-32. PubMed ID: 7178646
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The mode of action of sulpiride as an atypical antidepressant agent.
    Jenner P; Marsden CD
    Adv Biochem Psychopharmacol; 1982; 32():85-103. PubMed ID: 7046370
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dopamine receptor mediated antidepressant action of B-HT 920 in mice.
    Sharma A; Kulkarni SK
    Indian J Exp Biol; 1994 Mar; 32(3):172-5. PubMed ID: 8070836
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of dopamine and dopamine antagonists on postprandial release of pancreatic polypeptide in dogs and in healthy volunteers.
    Linnestad P; Guldvog I; Schrumpf E
    Scand J Gastroenterol; 1983 Jan; 18(1):81-5. PubMed ID: 6144173
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The inhibition of ganglionic transmission via presynaptic dopamine DA1 and postsynaptic DA2 receptor activation in the canine cardiac sympathetic ganglia.
    Mukai M; Kushiku K; Yamada H; Yamada K; Dan K; Furukawa T
    J Pharmacol Exp Ther; 1996 Nov; 279(2):822-9. PubMed ID: 8930189
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Intestinal pharmacomanometry and glucose tolerance: evidence for two antagonistic dopaminergic mechanisms in the human.
    Lechin F; van der Dijs B
    Biol Psychiatry; 1981 Oct; 16(10):969-86. PubMed ID: 7306619
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Peripheral pre- and post-synaptic dopamine receptors: are they different from dopamine receptors in the central nervous system?
    Goldberg LI; Kohli JD
    Commun Psychopharmacol; 1979; 3(6):447-56. PubMed ID: 546591
    [No Abstract]   [Full Text] [Related]  

  • 30. The significance of dopamine-receptor blockade for the mechanism of action of neuroleptic drugs.
    van Rossum JM
    Arch Int Pharmacodyn Ther; 1966 Apr; 160(2):492-4. PubMed ID: 5954044
    [No Abstract]   [Full Text] [Related]  

  • 31. Peripheral cardiovascular dopamine receptors.
    Pendleton RG; Setler PE
    Gen Pharmacol; 1977; 8(1):1-5. PubMed ID: 22476
    [No Abstract]   [Full Text] [Related]  

  • 32. Dopamine autoreceptors differ pharmacologically from postsynaptic dopamine receptors: effects of (-)-N-(2-chloroethyl)-norapomorphine.
    Lehmann J; Langer SZ
    Eur J Pharmacol; 1982 Jan; 77(1):85-6. PubMed ID: 7060630
    [No Abstract]   [Full Text] [Related]  

  • 33. Cardiovascular effects of reserpine, yohimbine, and reserpine-yohimbine mixtures on intact anesthetized dog.
    Luckens MM; Malone MH
    J Pharm Sci; 1973 Aug; 62(8):1286-90. PubMed ID: 4725172
    [No Abstract]   [Full Text] [Related]  

  • 34. Pharmacological analysis of adrenergic neurone blocking granatane derivatives.
    Dóda M; Molnár J; György L; Nádor K
    Acta Physiol Acad Sci Hung; 1967; 31(3):257-66. PubMed ID: 6067689
    [No Abstract]   [Full Text] [Related]  

  • 35. Comparison of the dopaminergic effects of N-substituted aporphines.
    Menon MK; Clark WG; Cannon JG
    J Pharm Pharmacol; 1976 Oct; 28(10):778-81. PubMed ID: 10377
    [No Abstract]   [Full Text] [Related]  

  • 36. Centrally acting emetics. 9. Hofmann and Emde degradation products of nuciferine.
    Cannon JG; Khonje PR; Long JP
    J Med Chem; 1975 Jan; 18(1):110-2. PubMed ID: 1109567
    [No Abstract]   [Full Text] [Related]  

  • 37. The effects of dopaminergic blocking agents on the glucose tolerance test in 6 humans and 6 dogs.
    Lechin F; Coll-García E; van der Dijs B; Bentolila A; Peña F; Rivas C
    Experientia; 1979 Jul; 35(7):886-7. PubMed ID: 477842
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pre- and post-synaptic activities of some dopamine analogues and related compounds [proceedings].
    Brown RA; Brown RC; O'Connor SE; Solca AM
    Br J Pharmacol; 1979 Nov; 67(3):420P-421P. PubMed ID: 497548
    [No Abstract]   [Full Text] [Related]  

  • 39. Anesthesia LXXII: anesthesia with deuterochloroform.
    Krantz JC; Koski WS; Loecher CK
    Biochem Pharmacol; 1967 Mar; 16(3):603-4. PubMed ID: 6034377
    [No Abstract]   [Full Text] [Related]  

  • 40. Proceedings of the British Pharmacological Society 8th-10th September, 1982. Abstracts.
    Br J Pharmacol; 1982 Dec; 77 Suppl(Suppl):445P-597P. PubMed ID: 7150878
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.